BCRX: Leadership change

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amended and Restated Stock Incentive Plan On June 11, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Company’s stockholders approved, by the affirmative vote of a majority of the shares of the Company’s common stock represented in person or by proxy at the Annual Meeting and voting on the proposal, a proposal to amend and restate the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (such plan, as amended and restated, the “Stock Incentive Plan”), increasing the number of shares available for issuance under the Stock Incentive Plan by 7,000,000 shares (the “Incentive Plan Proposal”). A detailed description of the Stock Incentive Plan is included in the Company’s Definitive Proxy Statement for the Annual Meeting. The description of the Stock Incentive Plan in this report does not purport to be complete and is qualified in its entirety by reference to the full text of the Stock Incentive Plan, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference. Item 5.07. Submission of Matters to a Vote of Security Holders. The Annual Meeting was held on June 11, 2026 for the purpose of (1) electing three directors to serve for a term ending at the Company’s 2029 annual meeting of stockholders and until a successor is duly elected and qualified; (2) ratifying the appointment of Ernst & Young LLP as the Company’s independent registered public accountants for 2026; (3) holding a non-binding, advisory vote approving the Company’s executive compensation; and (4) approving the Incentive Plan Propos